Longboard Pharmaceuticals (LBPH) Competitors

Longboard Pharmaceuticals (NASDAQ:LBPH) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Which has higher valuation & earnings, LBPH or CRBP?

Corbus Pharmaceuticals has higher revenue and earnings than Longboard Pharmaceuticals. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longboard Pharmaceuticals	N/A	N/A	-$54.42M	-$2.23	-26.82
Corbus Pharmaceuticals	$880K	241.78	-$44.60M	-$4.69	-3.72

Do insiders & institutionals have more ownership in LBPH or CRBP?

63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 4.6% of Longboard Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer LBPH or CRBP?

Corbus Pharmaceuticals received 385 more outperform votes than Longboard Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave Longboard Pharmaceuticals an outperform vote while only 66.87% of users gave Corbus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Longboard Pharmaceuticals	Outperform Votes 63 75.00%	Underperform Votes 21 25.00%
Corbus Pharmaceuticals	Outperform Votes 448 66.87%	Underperform Votes 222 33.13%

Is LBPH or CRBP more profitable?

Longboard Pharmaceuticals' return on equity of -33.03% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longboard Pharmaceuticals	N/A	-33.03%	-30.90%
Corbus Pharmaceuticals	N/A	-42.28%	-32.92%

Does the media prefer LBPH or CRBP?

In the previous week, Longboard Pharmaceuticals had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for Longboard Pharmaceuticals and 2 mentions for Corbus Pharmaceuticals. Longboard Pharmaceuticals' average media sentiment score of 1.50 beat Corbus Pharmaceuticals' score of 0.96 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longboard Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, LBPH or CRBP?

Longboard Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500.

Do analysts rate LBPH or CRBP?

Longboard Pharmaceuticals currently has a consensus target price of $59.56, suggesting a potential downside of 0.41%. Corbus Pharmaceuticals has a consensus target price of $65.86, suggesting a potential upside of 276.97%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Longboard Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longboard Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44
Corbus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Summary

Corbus Pharmaceuticals beats Longboard Pharmaceuticals on 10 of the 17 factors compared between the two stocks.